HAEMATOLOGY
Octanate
HAEMATOLOGY
Octanate
Octanate® 500 IU is a human plasma-derived coagulation factor VIII concentrate, naturally stabilised with von Willebrand factor (VWF)
Fast and Accurate Control
Octanate® 500 IU contains human coagulation factor VIII. It is naturally stabilised and protected by VWF, and is highly purified and efficacious1. Its efficacy and safety profile has been proven in the treatment and prevention of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency)2.
References
- Auerswald G. et al. The role of plasma-derived factor VIII/ von Willebrand factor concentrates in the treatment of Haemophilia A patients. Haematologica 2003; 88 (9): 21 – 25
- Summary of Product Characteristics of Octanate®
Octanate: Human plasma-derived coagulation factor VIII concentrate, naturally stabilised with von Willebrand factor (VWF)
Indication
octanate® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) of all age groups. This preparation is not indicated for von Willebrand disease.
Presentation
Available in vials of 250 IU, 500 IU and 1000 IU.
Key Features & Benefits
Effective in bleeding episodes
Good tolerability and efficacy in clinical trials in Previously Treated Patients (PTPs)
Low inhibitor risk in previously untreated patients (PUPs)
References
- Product information Octanate
- Internal data
- Klukowska, A et al. Ther Adv Hematol 2020, Vol. 11:1-12.
Key Features & Benefits
Over 20 years of clinical experience:
- Proven efficacy and safety profile in the treatment and prevention of bleeding in patients of all ages with haemophilia A1.
Effective inhibitor removal, even in patients with poor prognosis for ITI success2:
- Inhibitors eliminated in 79.2% of patients in median time of 3.9 months;
- Complete ITI success in 71% patients in a median time of 10.9 months;
- 86% reduction in mean monthly bleeding rate after inhibitor elimination.
Efficacy and reassuring incidence of inhibitors in previously untreated patients (PUPs)3:
- 90% of PUPs inhibitor free;
- No inhibitors in patients with non-null F8 mutations;
- Haemostatic efficacy rated as “excellent” in 99.6% of infusions;
- Haemostatic efficacy rated as “excellent” in 100% of surgical procedures.
References
- octanate Summary of Product Characteristics.
- Kreuz W et al. Haemophilia 2016; 22:87-95.
- Klukowska A et al. Haemophilia 2018; 24:211-8.
Related Brands
